Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Aims Prostate cancer is one of the most frequent causes of cancer death in men worldwide,
and novel drugs for prostate cancer therapies are still being developed. Palmitic acid is a …

PTEN is a phosphatase which metabolises PIP 3, the lipid product of PI 3-Kinase, directly
opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly …

Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the
gold standard options for treating prostate cancer (PCa). These are initially effective, as …

Abstract The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many
cellular processes and is frequently altered in cancer, contributing to tumor growth and …

MicroRNAs (miRNAs) play an important role in the biological process. Their expression and
functional changes have been observed in most cancers. Meanwhile, there exists …

Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …

Prostate cancer (PCa) is the second most common malignancy among men in the world.
Castration-resistant prostate cancer (CRPC) is the lethal form of the disease, which …